Preclinical Evaluation of Lipid-Based Nanosystems (Record no. 3019292)

MARC details
000 -LEADER
fixed length control field 05966naaaa2201453uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/76594
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220714193957.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number books978-3-0365-1549-6
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783036515502
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783036515496
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3390/books978-3-0365-1549-6
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
072 #7 - SUBJECT CATEGORY CODE
Subject category code TB
Source bicssc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Silva, Ana Catarina
Relator code edt
9 (RLIN) 1620600
245 10 - TITLE STATEMENT
Title Preclinical Evaluation of Lipid-Based Nanosystems
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Place of publication, distribution, etc Basel, Switzerland
Name of publisher, distributor, etc MDPI - Multidisciplinary Digital Publishing Institute
Date of publication, distribution, etc 2021
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (351 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
-- https://creativecommons.org/licenses/by/4.0/
-- cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Technology: general issues
Source of heading or term bicssc
9 (RLIN) 928609
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanostructured lipid carriers (NLC)
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term formulation optimization
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term rivastigmine
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term quality by design (QbD)
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nasal route
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nose-to-brain
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term N-alkylisatin
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term liposome
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term urokinase plasminogen activator
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term PAI-2
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term SerpinB2
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term breast cancer
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term liposomes
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term target delivery nanosystem
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term FZD10 protein
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term colon cancer therapy
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term supersaturation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term silica-lipid hybrid
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term spray drying
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipolysis
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipid-based formulation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term fenofibrate
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term mesoporous silica
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term oral drug delivery
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hyaluronic acid
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term drug release
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term light activation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term stability
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term mobility
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term biocorona
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term dissolution enhancement
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term phospholipids
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term solid dosage forms
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term porous microparticles
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanoemulsion(s)
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term phase-behavior
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term DoE
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term D-optimal design
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term vegetable oils
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term non-ionic surfactants
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term efavirenz
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term flaxseed oil
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanostructured lipid carriers
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanocarrier
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term docohexaenoic acid
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term neuroprotection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term neuroinflammation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term fluconazole
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Box‒Behnken design
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanotransfersome
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ulcer index
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term zone of inhibition
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term rheological behavior
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ex vivo permeation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term nanomedicine
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term cancer
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term doxorubicin
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term melanoma
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term drug delivery
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ultrasound contrast agents
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term phospholipid coating
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ligand distribution
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term cholesterol
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term acoustic response
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term microbubble
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipid phase
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term dialysis
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ammonia
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term intoxication
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term cyanocobalamin
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term vitamin B12
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term atopic dermatitis
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term psoriasis
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term transferosomes
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipid vesicles
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term skin topical delivery
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term oligonucleotide
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term self-emulsifying drug delivery systems
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hydrophobic ion pairing
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term intestinal permeation enhancers
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Caco-2 monolayer
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term clarithromycin
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term solid lipid nanoparticles
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term optimization
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term permeation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term pharmacokinetics
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term follicular targeting
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term dexamethasone
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term alopecia areata
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipomers
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term lipid polymer hybrid nanocapsules
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term biodistribution
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term skin
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term ethyl cellulose
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term n/a
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sousa Lobo, José Manuel
Relator code edt
9 (RLIN) 1620601
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Silva, Ana Catarina
Relator code oth
9 (RLIN) 1620600
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sousa Lobo, José Manuel
Relator code oth
9 (RLIN) 1620601
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://mdpi.com/books/pdfview/book/4039">https://mdpi.com/books/pdfview/book/4039</a>
-- 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/76594">https://directory.doabooks.org/handle/20.500.12854/76594</a>
-- 0
Public note DOAB: description of the publication
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Date acquired Total Checkouts Date last seen Price effective from Koha item type
        E-Books Open Access OPJGU Sonepat- Campus OPJGU Sonepat- Campus 14/07/2022   14/07/2022 14/07/2022 Electronic-Books

O.P. Jindal Global University, Sonepat-Narela Road, Sonepat, Haryana (India) - 131001

Send your feedback to glus@jgu.edu.in

Hosted, Implemented & Customized by: BestBookBuddies   |   Maintained by: Global Library